(Nasdaq: GELS) Gelteq Limited Announces 400,000 Units Enter into Production in November 2024

*Sponsored by OEJ Enterprises (Nasdaq: GELS) Gelteq Limited Announces 400,000 Units Enter into Production in November 2024 (Nasdaq: GELS)  Greetings FDR Subscribers, This is Michael Reece with “FinancialDrivenResearch” delivering you your new premium biotech breakout alert for the Monday 12/2 trading session, Gelteq Limited (NASDAQ: GELS). Gelteq Limited is a biotechnology company specializing in the development and commercialization of gel-based delivery systems for various applications. Founded in 2017 and headquartered in Caulfield, Australia, Gelteq focuses on innovative, ingestible gel solutions that cater to both human and animal needs. Its product portfolio includes formulations for prescription drugs, nutraceuticals, over-the-counter products, sports supplements, and pet care. Gelteq’s unique gel technology is designed for improved delivery and absorption of active ingredients, providing an alternative to traditional pills and liquids. These customizable gel formulations are marketed under a white-label model, allowing businesses to adapt the technology for specific applications and branding needs. Recent Developments The company went public on the NASDAQ in October 2024, raising $5.2 million in its initial public offering. This capital supports Gelteq’s expansion efforts, particularly in the United States, where it has appointed Adam Bendell as President of U.S. Operations to scale domestic business activities. As of November 2024, Gelteq has announced the production of 400,000 gel-based units to meet growing demand. [Gelteq Announces 400,000 Units Enter into Production in November 2024]( NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- [Gelteq Limited]( (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss. Gelteq Co-Founder and CEO Nathan Givoni stated, “Our recent IPO was undertaken to provide the necessary capital and awareness of our technology to commence larger scale sales, whilst balancing our research and development activities. To see such volumes entering production so soon after the IPO is a testament to our team executing our plans, together with market validation on our gel-based technology. This production run demonstrates our ability to sell our products to end-users across the world and our ability to begin deriving revenues in the near term.” Gelteq Co-Founder and Executive Chairman Simon Szewach stated, “Earlier this year, we strengthened our partnership with Monash Innovation Labs, which allows us to effectively scale and meet our client needs, while ensuring the quality of products. The orders connected to this production run are substantial and we believe that they represent the start of even larger volume orders to come.” About Gelteq Inc. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit [www.gelteq.com](. Market and Strategy Gelteq operates in the healthcare sector, particularly within the pharmaceutical industry. Its products aim to address consumer demand for convenient and effective delivery methods for dietary supplements, medications, and other health products. The company's entry into the U.S. market is a strategic move to access a larger consumer base and capitalize on the growing interest in advanced drug delivery technologies. Future Outlook With its innovative gel-based platform and strategic expansion into key markets, Gelteq positions itself as a disruptor in the pharmaceutical and nutraceutical sectors. The company’s success will depend on its ability to scale production efficiently, attract partnerships, and maintain the quality and reliability of its delivery systems. For more details, you can explore their official website or follow recent announcements on financial platforms. To Your Trading Success, Michael Reece Editor, Financial Driven Research Sources: [( [( [( [( [( [( [( [( © 2024 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates have been compensated twenty thousand USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc]( and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](